+44 20 8123 2220
info@marketpublishers.com

Global Cancer Immunotherapy Market & Clinical Trials Outlook 2022

https://marketpublishers.com/r/PB08CEFF87AEN.html
Date: April 2017
Pages: 280
Price: US$ 2,400.00 (Single User License)
ID: PB08CEFF87AEN

Abstracts

Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.

“Global Cancer Immunotherapy Market & Clinical Trials Outlook 2022” report gives comprehensive insight on clinical and non-clinical developments in the field of cancer immunotherapy. As per report findings, cancer immunotherapy has emerged as the new growth frontier for the pharmaceutical companies involved in the clinical research and development of cancer drugs and therapeutics. Currently there are more than 2000 cancer immunotherapies based drugs/therapies are in clinical pipeline. Majority of these are in preclinical, Phase-I and Phase-II trials. There are 14 cancer vaccine, 44 Cancer monoclonal antibodies, 3 cancer cell therapies and 61 cancer Immunomodulators are commercially available in the market.

Pharmaceutical companies are actively engaged in research and development of cancer immunotherapies because of large unmet medical necessities. Investigators are trying to come forth with innovative cancer immunotherapeutic products having high safety and efficacy profiles which are not offered by conventional therapeutics. Higher investments in research and development segment could significantly increase the drug discovery rates which will alleviate the medical condition of cancer patients. Simultaneously, technological advancements are being made due to which development of worthy candidates with high commercialization and pharmacological potential is expected to increase in coming years.

Investigators are trying to decipher underlying principle of cancer progression and proliferation. Different cancer indications have different requirements for developing effective therapeutics due to which identification of these factors have become important. This knowledge would be used for developing innovative cancer

immunotherapies for various malignancies.

Cancer immunotherapeutics based on these discoveries would pave path for market introduction of highly effective therapeutics. Some progress has been made which could be noticed by observing plethora of cancer immunotherapeutics available for different cancer indications. Their clinical pipeline is also developing rapidly and various products are at different stages of clinical trials. They are expected to offer severe competition to presently available cancer therapeutics with modest pharmacological efficacy.

Cancer immunotherapies have been used for limited number of malignancies as compared to other drug categories. Mostly hematological malignancies like follicular lymphoma, chronic lymphocytic leukemia and diffuse large B cell non-Hodgkin's lymphoma have remained the focal point. Other cancer indications like melanoma, NSCLC, prostate cancer and RCC have also got cancer immunotherapeutics.

Most like, cancer therapeutics in clinical trials would be able to present positive data that will allow them to easily enter in global market. Cancer incidences are escalating rapidly and cancer immuno therapeutics seems to play an important role in offering better medical care to patients. Some of them have received FDA's accelerated approval and breakthrough therapy designation due to their superior pharmacological benefits. It is expected that similar progress would be shown by cancer immunotherapeutics under development for different malignancies.

"Global Cancer Immunotherapy Market & Clinical Trials Outlook 2022" report highlights:

Categorization of Cancer Immunotherapy

Market Aspects of Cancer Immunotherapy

Clinical Trials & Development Insight

Global Cancer Immunotherapy Pipeline Overview

Marketed Cancer Immunotherapy by Class

Global Cancer Immunotherapy Market Future Prospects

Competitive Analysis

+44 20 8123 2220
info@marketpublishers.com

+44 20 8123 2220
info@marketpublishers.com

Contents

1. IMMUNOTHERAPY: MENDING CANCER REGIMENS

1.1 Preface to Cancer Immunotherapy
1.2 Evolution of Cancer Immunotherapy

2. CATEGORIZATION OF CANCER IMMUNOTHERAPY

2.1 Specific Cancer Immunotherapy
  2.1.1 Cancer Vaccines
  2.1.2 Monoclonal Antibodies
2.2 Non-Specific Cancer Immunotherapy
  2.2.1 Adoptive Cell Transfer Immunotherapy
  2.2.2 Immune Checkpoint Inhibitors

3. FUNDAMENTALS OF CANCER VACCINES

3.1 Prologue of Cancer Vaccines
3.2 Cancer Vaccines in Immunotherapy
3.3 Commercial Aspects of Cancer Vaccines

4. NEW ERA OF MONOCLONAL ANTIBODIES

4.1 Rudiments of Monoclonal Antibodies
4.2 Advents of Monoclonal Antibodies
4.3 Commercial Aspects of Monoclonal Antibodies

5. TRAILS OF T-CELL THERAPIES

5.1 Adoptive Cell Transfer Technology
5.2 Strategies of Adoptive Cell Transfer
5.3 Commercial Aspects of Adoptive Cell Therapy

6. ASPECTS OF IMMUNE CHECKPOINT INHIBITORS

6.1 Prelude to Immune Checkpoint Inhibitors
6.2 Implications of Immunecheck Point Inhibitors
6.3 Commercial Aspects of Immune Checkpoint Inhibitors

+44 20 8123 2220
info@marketpublishers.com

7. IMMUNOMODULATORS IN CANCER IMMUNOTHERAPY

7.1 Perspective of Immunomodulators
7.2 Clinical Aspects of Immunomodulators
7.3 Commercial Aspects of Immunomodulators

8. ONCOLYTIC VIRAL IMMUNOTHERAPY

8.1 Concept to Oncolytic Viruses
8.2 Potential Approaches of Oncolytic Viruses
8.3 Commercial Aspects of Oncolytic Viruses

9. CYTOKINES IN CANCER IMMUNOTHERAPY

9.1 Fundamentals of Cytokines
9.2 Classification of Cytokines
9.3 Commercial Aspects of Cytokines

10. INTERFERONS IN IMMUNOTHERAPY

10.1 Potentials of Interferons
10.2 Classification of Interferons
10.3 Clinical Applications of Interferons

11. INTERLEUKINS IN IMMUNOTHERAPY

11.1 Potentials of Interleukins
11.2 Clinical Applications of Interleukins

12. GM-CSF IN IMMUNOTHERAPY

12.1 Potentials of GM-CSF
12.2 Clinical Applications of GM-CSF

13. GLOBAL ECONOMIC EVALUATIONS

13.1 Economic Aspects of Cancer Immunotherapy
13.2 Cancer Immunotherapy Cost by Product

+44 20 8123 2220
info@marketpublishers.com

14. MARKET ASPECTS OF CANCER IMMUNOTHERAPY

14.1 Current Market Trends
14.2 Cancer Immunotherapy Pipeline Overview

15. GLOBAL CANCER IMMUNOTHERAPY MARKET DYNAMICS

15.1 Favorable Market Parameters
15.2 Commercialization Challenges

16. MARKETED CANCER CELL THERAPIES DRUGS

16.1 Sipuleucel-T (Provenge®)
16.2 T-Lymphocyte Cell Therapy(Immuncell-LC®)

17. MARKETED CANCER CYTOKINES DRUGS

17.1 Aldesleukin (Proleukin®)
17.2 Denileukin Diftitox (ONTAK®)
17.3 Interferon Alpha (Multiferon®)
17.4 Interferon Alpha-2a (Roferon-A®)
17.5 Interferon Alpha-2a (Veldona®)
17.6 Interferon Alpha-2a Biosimilar(Inferon™/Inmutag™)
17.7 Interferon Alpha-2b(Intron® A)
17.8 Interferon Alpha-2b Biosimilar(Bioferon™)
17.9 Interferon Alpha-2b Biosimilar (Intalfa®)
17.10 Interferon Alpha-2b Biosimilar
17.11 Interferon-Alpha-n3 (Alferon N®)
17.12 Interferon-Beta-1b (Feron®)
17.13 Interferon-Gamma (Ogamma®)
17.14 Interleukin-2 Biosimilar (Ilcass)
17.15 Teceleukin (Imunace™)

18. MARKETED CANCER VACCINES

18.1 Bladder Cancer Vaccine (PACIS®)
18.2 Bladder Cancer Vaccine
18.3 BV NSCLC

18.4 Dendritic Cell Vaccine (CreaVax-HCC®, CreaVax-PC® & CreaVax-RCC®)
18.5 Human Papillomavirus Vaccine Quadrivalent (Gardasil®/Silgard®)
18.6 Human Papillomavirus Vaccine Recombinant Bivalent (Cervarix®)
18.7 Melanoma Vaccine (MVax®)
18.8 Melanoma Vaccine (Melacine®)
18.9 Racotumomab (Vaxira®)
18.10 Sipuleucel-T (Provenge®)
18.11 Tertomotide (LucaVax)
18.12 Vitespen (Oncophage®)

19. MARKETED CANCER MONOCLONAL ANTIBODIES

19.1 Bevacizumab
19.2 Trastuzumab Emtansine
19.3 Trastuzumab Subcutaneous
19.4 Brentuximab Vedotin
19.5 Catumaxomab
19.6 Ipilimumab
19.7 Nivolumab
19.8 Pembrolizumab
19.9 Pertuzumab
19.10 Rituximab
19.11 Trastuzumab

20. GLOBAL CANCER IMMUNOTHERAPY MARKET FUTURE PROSPECTS

21. COMPETITIVE LANDSCAPE

21.1 Abbvie
21.2 Advaxis
21.3 Altor BioScience
21.4 Amgen
21.5 Biogen Idec
21.6 Biogenomics
21.7 Celldex Therapeutics
21.8 Dendreon Corporation
21.9 Eli Lilly
21.10 Expression Genetics
21.11 Galena Biopharma

+44 20 8123 2220
info@marketpublishers.com

21.12 Genmab
21.13 Gilead Sciences
21.14 GlaxoSmithKline
21.15 ImmunoCellular Therapeutics
21.16 ImmunoGen
21.17 Inovio Pharmaceuticals
21.18 IRX Therapeutics
21.19 Merck
21.20 NeoStem Oncology
21.21 NewLink Genetics
21.22 Northwest Biotherapeutics
21.23 Novartis
21.24 Peregrine Pharmaceuticals
21.25 Pfizer
21.26 Philogen
21.27 Regulon
21.28 Roche
21.29 Seattle Genetics
21.30 ZymoGenetics

+44 20 8123 2220
info@marketpublishers.com

List Of Figures

LIST OF FIGURES

Figure 1-1: Evolutionary Trails of Cancer Immunotherapy
Figure 1-2: Layout of Necessity of Cancer Immunotherapies for Cancer Treatment
Figure 1-3: Potential Benefits of Cancer Immunotherapies
Figure 2-1: Classification of Cancer Immunotherapies
Figure 2-2: Categorization of Specific Immunotherapy
Figure 2-3: Non-Specific Cancer Immunotherapies
Figure 3-1: Categorization & Function of Cancer Vaccines
Figure 3-2: Mechanism of the Cancer Vaccine towards Tumor Eradication
Figure 3-3: Global Cancer Vaccines Market (US$ Billion), 2016-2022
Figure 4-1: Process of Manufacturing of Monoclonal Antibody
Figure 4-2: Principles of Monoclonal Antibodies
Figure 4-3: Evolution of Monoclonal Antibody over Generations
Figure 4-4: Classification of Monoclonal Antibodies
Figure 4-5: Representation of Mechanism of Alemtuzumab
Figure 4-6: Representation of Mechanism of Ibritumomab Tiuxetan
Figure 4-7: Representation of Mechanism of Blinatumomab
Figure 4-8: Global Market for Cancer Monoclonal Antibodies (US$ Billion), 2016-2022
Figure 5-1: Benefit of Adoptive Cell Transfer Immunotherapy
Figure 5-2: Systematic Representation of Adoptive T-Cell Therapies
Figure 5-3: Three Adoptive Cell Transfer Strategies for Cancer Immunotherapy
Figure 5-4: Tumor-Infiltrating Lymphocytes in Adoptive Cell Transfer
Figure 5-5: Mechanism of CAR Modified T-Cells
Figure 5-6: Genetically Engineered TCR for Cancer Immunotherapy
Figure 5-7: Global Predictive Market of CAR T-Cell Therapeutics (US$ Million), 2016-2022
Figure 6-1: Benefits of Immune Checkpoint Inhibitors
Figure 6-2: Implication of Adaptive Immune Resistance Mechanism
Figure 6-3: Mechanism of Ipilimumab
Figure 6-4: Layout of Mechanism of Nivolumab
Figure 6-5: Mechanism of Pembrolizumab
Figure 6-6: Global - Immune Check Point Inhibitors Market (US$ Billion), 2016-2022
Figure 7-1: Functions of Immunomodulators
Figure 7-2: Benefits of Immunomodulators
Figure 7-3: Layout of the Challenges of Immunomodulators
Figure 7-4: Properties of Thalidomide

Figure 7-5: Mechanism of Lenalidomide In Vivo
Figure 7-6: Mechanism of Lenalidomide in Vitro
Figure 7-7: Mechanism of Pomalidomide
Figure 7-8: The Global Market for Immunomodulators for All Indications (US$ Billion), 2016-2022
Figure 8-1: Demonstration of Categorization of Oncolytic Viruses
Figure 8-2: Potential Advantages of Oncolytic Viruses over Conventional Therapies
Figure 8-3: The Predicted Market Share of Oncolytic Viral Therapies (US$ Million), 2016-2022
Figure 9-1: Layout of Functions Performed by Cytokine
Figure 9-2: Benefits of Cytokines in Cancer Immunotherapy
Figure 9-3: Classification of Cytokine Receptor Family
Figure 9-4: Percentage Share of the Cancer Immunotherapies by the Technology
Figure 10-1: Layout of Functions of Interferon
Figure 10-2: Classification of Interferons on the Basis of Types of Genes
Figure 10-3: General Mechanism of Interferons
Figure 10-4: Mechanism of Interferon Alfa-n3
Figure 10-5: Aspects of Peginterferon Alfa-2a
Figure 10-6: Applications of Interferon Beta 1a
Figure 10-7: Potentials of Interferon Alfa-2b
Figure 11-1: Functions of Interleukin
Figure 11-2: Potentials of Interleukins in Cancer Immunotherapy
Figure 11-3: Clinical Potentials of Proleukin
Figure 11-4: Clinical Potentials of Denileukin Diftitox
Figure 12-1: Potential Applications of GM-CSF
Figure 12-2: Mechanism of Sargramostim
Figure 13-1: Expected Cancer Treatment Cost (US$ Billion), 2016-2022
Figure 13-2: Comparative Analysis of Available Cancer Treatments
Figure 13-3: Major Approved Immunotherapeutic Drugs
Figure 13-4: Annual per Patient Drug Expenditure of Immunotherapy
Figure 14-1: Global Cancer Immunotherapeutic Market (US$ Billion), 2016-2022
Figure 14-2: Global - Cancer Vaccine Clinical Pipeline by Phase (%), 2017 - 2022
Figure 14-3: Global - Cancer Vaccine Clinical Pipeline by Phase (Number), 2017 -2022
Figure 14-4: Global - Cancer Vaccine Suspended/Discontinued in Clinical Pipeline by Phase (%), 2017 -2022
Figure 14-5: Global - Cancer Vaccine Suspended/Discontinued in Clinical Pipeline by Phase (Number), 2017 -2022
Figure 14-6: Global - Cancer Monoclonal Antibodies Clinical Pipeline by Phase (%), 2017 -2022

+44 20 8123 2220
info@marketpublishers.com

Figure 14-7: Global - Cancer Monoclonal Antibodies Clinical Pipeline by Phase (Number), 2017 -2022
Figure 14-8: Global - Cancer Cell Therapies Clinical Pipeline by Phase (%), 2017 -2022
Figure 14-9: Global - Cancer Cell Therapies Clinical Pipeline by Phase (Number), 2017 -2022
Figure 14-10: Global - Cancer Cell Therapies Suspended/Discontinued in Clinical Pipeline by Phase (%), 2017 -2022
Figure 14-11: Global - Cancer Cell Therapies Suspended/Discontinued in Clinical Pipeline by Phase (Number), 2017 - 2022
Figure 14-12: Global - Cancer Immunomodulators Clinical Pipeline by Phase (%), 2017 - 2022
Figure 14-13: Global - Cancer Immunomodulators Clinical Pipeline By Phase (Number), 2017 - 2022
Figure 15-1: Favorable Cancer Immunotherapy Market Parameters
Figure 15-2: Cancer Immunotherapy Commercialization Challenges
Figure 21-1: Advaxis Clinical Pipeline
Figure 21-2: Celldex Therapeutics Clinical Pipeline
Figure 21-3: Expression Genetics Clinical Pipeline
Figure 21-4: Galena Biopharma Clinical Pipeline
Figure 21-5: ImmunoCellular Therapeutics Clinical Pipeline
Figure 21-6: ImmunoGen Clinical Pipeline
Figure 21-7: Inovio Pharmaceuticals Clinical Pipeline
Figure 21-8: NewLink Genetics Corporation Clinical Pipeline
Figure 21-9: Northwest Biotherapeutics Clinical Pipeline
Figure 21-10: Peregrine Pharmaceuticals Clinical Pipeline
Figure 21-11: Philogen Clinical Pipeline
Figure 21-12: Seattle Genetics Clinical Pipeline

+44 20 8123 2220
info@marketpublishers.com

List Of Tables

LIST OF TABLES

Table 4-1: Different Monoclonal Antibodies Used in Cancer Immunotherapy
Table 6-1: Illustration of Some Important Checkpoint Inhibitors
Table 9-1: Few Important Immunocytokines under Clinical Development
Table 9-2: Some Pharmacologically Important Cytokines Used in Cancer Immunotherapies
Table 14-1: Few Commercially Important PD-1 Drugs

+44 20 8123 2220
info@marketpublishers.com

I would like to order

Product name: Global Cancer Immunotherapy Market & Clinical Trials Outlook 2022

Product link: https://marketpublishers.com/r/PB08CEFF87AEN.html

Price: US$ 2,400.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:
info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/PB08CEFF87AEN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:

Last name:

Email:

Company:

Address:

City:

Zip code:

Country:

Tel:

Fax:

Your message:

**All fields are required

Custumer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below
and fax the completed form to +44 20 7900 3970